BrightPath Biotherapeutics Co.,Ltd. [4594.T]
TOKYO, Mar 30 (Pulse News Wire) – Brightpath Biotherapeutics CO.,LTD. (4594.T) completed the recovery of settlement payments totaling $15.108 million related to unresolved clinical trial expenses in the United States.
The company had initiated legal proceedings against Rosenstein Research, Ltd. on February 27, 2024, leading to a court-approved settlement agreement.
Under this agreement, BrightPath received payments of $4.539 million in the fourth quarter of its fiscal year ending March 2025, and further installments of $4.422 million and $4.681 million (estimated) in subsequent quarters. The recovered funds have been recorded as extraordinary income across various accounting periods, contributing significantly to the company's financial performance.
Specifically, the total amount was recognized as follows: - Fiscal Year Ending March 2025: $15.108 million - Estimated for the Fiscal Year Ending March 2026: $12.0 million Looking ahead, BrightPath expects no impact on its financial results for the fiscal year ending March 2026 due to this settlement.
🟢 Confidence: High AI-translated content.